Postoperative complications after induction chemoradiotherapy in patients with non-small-cell lung cancer

Abstract
Surgical resection is still the best curative therapy for non-small-cell lung cancer (NSCLC); however, surgery alone is not adequate for most cases, considering a 5-year survival rate of less than 15% in stage IIIA-N2 disease and approximately 50% in T2N0 disease [1]. The theoretical advantages of pre-operative induction therapy lie in a potential increase in the resectability rate and a lower rate of distant relapse owing to eradication of micrometastases, both of which may contribute to achieving long-term survival for these patients. After encouraging results of several clinical trials for patients in stage IIIA-N2 disease [2,3], the concept of induction therapy followed by surgical resection found general acceptance and is now being adopted in patients with earlier stages of the disease.

This publication has 0 references indexed in Scilit: